Development of Peptide Antibiotic Nucleic Acids
Development of Peptide Antibiotic Nucleic Acids
批准号:
8780584
负责人:
DEV PRIYA ARYA
金额:
$29.58万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-20 至 2016-05-31
关键词:
AddressAmino SugarsAminoglycosidesAnimalsAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsAntimicrobial ResistanceAwarenessBacteriaBacterial InfectionsBacterial ProteinsBase PairingBindingBiological AssayBooksBostonBypassCell LineCell physiologyCellsCessation of lifeCommunicable DiseasesComplementComplexCongressesDevelopmentDiseaseDrug DesignDrug TargetingDrug resistanceEnzymesEpidemicEscherichia coliGenerationsGrowthHeadHealth Care CostsHigh Pressure Liquid ChromatographyHumanHybridsIn VitroInfectionInstitute of Medicine (U.S.)KnowledgeLeadLibrariesLinkLocalesMalariaMarketingMethodsNeomycinNosocomial InfectionsNucleic AcidsOrganic SynthesisParasitesPeptide AntibioticsPeptide Nucleic AcidsPharmaceutical PreparationsPhasePredispositionPreparationProtein BiosynthesisRNA BindingRNA InterferenceReportingResearchResistanceRibosomal RNARibosomesSiteSolidSolutionsSpecificityStaphylococcal InfectionsStructureSurgeonTailTechnologyTestingTherapeuticThioureaTimeToxic effectTranslationsTuberculosisUnited StatesUnited States National Academy of SciencesUniversitiesValidationVirusWorkWorld Healthantimicrobialantimicrobial drugbacterial resistancecombatcomparativecostdesignfightinginnovationmicroorganismmultidisciplinarynovelnovel therapeuticspublic health relevancescale upscreeningsmall moleculesuccesstherapeutic targetuptakeweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. The world is rapidly heading towards a pre-1940's scenario when it comes to fighting infectious disease. Antimicrobial resistance is a growing problem on a global scale, greatly hampering our abilities to quell worldwide epidemics such as tuberculosis and malaria, as well as the simple staphylococcus infection. Unless innovative strategies are developed to produce robust and effective new classes of antibiotics, health care costs will continue to climb and we will completely lose our ability to combat even the most common infection. Nucleic acids are avenues for drug design, both as therapeutics and as targets. Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific ribosomal targeting oligomers as antibacterials. Complexes between ribosomal components will be exploited as targets for small molecule drug libraries that- inactivate the ribosome, stopping bacterial protein synthesis and causing bacterial
death. NUBADs unique experimental approaches and technologies will allow us to target ribosomal regions not previously explored for susceptibility against anti-bacterial agents. This work addresses an important world health issue, antimicrobial resistance, and presents creative steps towards a novel solution to this problem. The work proposed here, a multidisciplinary effort encompassing solid-phase organic synthesis, RNA targeted screening and antibacterial studies, describes the development of sequence-specific cell permeable binders of rRNA as antibacterial therapeutics. The success of the proposed work would be a significant addition to currently available ribosome-specific approaches in antibacterial therapy. We propose using a small rRNA target sequences to design conjugates that can be employed to inhibit bacterial growth, opening possibilities for developing sequence-specific RNA targeted therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of peptide nucleic acid antibiotics
-
批准号:10347347
-
项目类别:
-
资助金额:$99.96万
-
财政年份:2021
-
负责人:DEV PRIYA ARYA
-
依托单位:
Delivery of chemically modified PNA oligomers
-
批准号:10006671
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2020
-
负责人:DEV PRIYA ARYA
-
依托单位:
Aminoglycosides with reduced ototoxicity
-
批准号:10156973
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2020
-
负责人:DEV PRIYA ARYA
-
依托单位:
Aminoglycosides with reduced ototoxicity
-
批准号:10377538
-
项目类别:
-
资助金额:$99.97万
-
财政年份:2020
-
负责人:DEV PRIYA ARYA
-
依托单位:
Aminoglycosides with reduced ototoxicity via miRNA targeting
-
批准号:9891947
-
项目类别:
-
资助金额:$39.77万
-
财政年份:2019
-
负责人:DEV PRIYA ARYA
-
依托单位:
Aminoglycosides with reduced ototoxicity via miRNA targeting
-
批准号:9982540
-
项目类别:
-
资助金额:$4.49万
-
财政年份:2019
-
负责人:DEV PRIYA ARYA
-
依托单位:
Screening the Ribosome for New Target Sites
-
批准号:9140721
-
项目类别:
-
资助金额:$32.5万
-
财政年份:2016
-
负责人:DEV PRIYA ARYA
-
依托单位:
Aminoglycosides with reduced ototoxicity
-
批准号:9197240
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2016
-
负责人:DEV PRIYA ARYA
-
依托单位:
Targeting RNA conformation for drug development
-
批准号:8252970
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2012
-
负责人:DEV PRIYA ARYA
-
依托单位:
A Rapid assay for RNA targeted drugs: Instrumentation Supplement
-
批准号:9120576
-
项目类别:
-
资助金额:$8.16万
-
财政年份:2011
-
负责人:DEV PRIYA ARYA
-
依托单位:
A Rapid Assay for RNA Targeted Drugs
-
批准号:8715189
-
项目类别:
-
资助金额:$68.47万
-
财政年份:2011
-
负责人:DEV PRIYA ARYA
-
依托单位:
A novel assay for RNA targeted drugs
-
批准号:8203072
-
项目类别:
-
资助金额:$28.55万
-
财政年份:2011
-
负责人:DEV PRIYA ARYA
-
依托单位:
A Rapid Assay for RNA Targeted Drugs
-
批准号:8884616
-
项目类别:
-
资助金额:$66.37万
-
财政年份:2011
-
负责人:DEV PRIYA ARYA
-
依托单位:
Development of Ets2-Inhibitors
-
批准号:7847347
-
项目类别:
-
资助金额:$17.52万
-
财政年份:2009
-
负责人:DEV PRIYA ARYA
-
依托单位:
Development of Ets2-Inhibitors
-
批准号:7458423
-
项目类别:
-
资助金额:$22.24万
-
财政年份:2008
-
负责人:DEV PRIYA ARYA
-
依托单位:
海外基金